Loading stock data…
NEOG
$9.53+0.13 (+1.38%)
Market ClosedLast close May 1
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neogen Corporation in the Healthcare sector is trading at $9.53. The stock is currently 17% below its 52-week high of $11.43, remaining 27.4% above its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why NEOG maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.53
Potential Upside
5%
Whystock Fair Value$10.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Buy
Mean target$12.00+25.9%
Range$11.00 – $13.00
Fundamentals
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-51.94%
Volume
Today's trading volume
1.87M
Recent News
1 of Wall Street’s Favorite Stock to Target This Week and 2 Facing Challenges
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
3 Reasons NEOG is Risky and 1 Stock to Buy Instead
What a fantastic six months it’s been for Neogen. Shares of the company have skyrocketed 53.5%, hitting $9.46. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
5 Must-Read Analyst Questions From Neogen’s Q1 Earnings Call
Neogen’s first quarter results were shaped by contrasting trends across its business lines. Management cited continued core growth in the Food Safety segment, particularly in the United States, while acknowledging significant supplier-driven disruptions in the Animal Safety business. CEO Mikhael Nassif noted, “We encountered several supplier challenges stemming from third-party manufacturers that unfortunately had a meaningful impact on our Animal Safety business.” The company responded by stren
1 Unprofitable Stock on Our Watchlist and 2 Facing Challenges
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
2 Small-Cap Stocks Worth Investigating and 1 We Avoid
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.